Oric Pharmaceuticals (ORIC) Price & Analysis

Compare

494 Followers

ORIC Stock Chart & Stats

$11.16

-$0.67(-7.21%)

At close: Jan 08 4:00 PM EST

$11.16

-$0.67(-7.21%)

Day’s Range― - ―

52-Week Range$3.90 - $14.93

Previous CloseN/A

Volume181.02K

Average Volume (3M)1.50M

Market Cap

$1.12B

Enterprise Value$1.09B

Total Cash (Recent Filing)$281.49M

Total Debt (Recent Filing)$11.55M

Price to Earnings (P/E)―

Beta1.33

Next Earnings

May 11, 2026

EPS Estimate

-0.32

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.30

Shares Outstanding100,358,240

10 Day Avg. Volume1,616,706

30 Day Avg. Volume1,503,086

Financial Highlights & Ratios

PEG Ratio0.28

Price to Book (P/B)1.87

Price to Sales (P/S)0.00

P/FCF Ratio-6.30

Enterprise Value/Market Cap0.97

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-3.39K

Enterprise Value/Ebitda-8.12

Forecast

1Y Price Target

$20.30

Price Target Upside81.90% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-1.41

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Brain Metastases EfficacyAnalyst notes enozertinib's demonstrated systemic and brain responses in patients with active brain metastases, suggesting potential to address an unmet need for therapies that penetrate the brain and differentiate the lung cancer program.

Clinical Development PathDose optimization results for ORIC-944 that define recommended combination doses could enable a registrational late-stage trial in metastatic castration-resistant prostate cancer, clarifying the program's path to approval and value creation.

Safety DifferentiationAnalyst highlights that rinzimetostat's distinct mechanism of action and absence of reported secondary malignancies in early studies reduce the likelihood of a class-wide safety issue and could support a re-rating if safety remains clean.

Bears Say

Class Safety ConcernsVoluntary withdrawal of a peer drug over reports of secondary blood cancers has raised class-level safety concerns, increasing regulatory scrutiny and pressuring investor sentiment for related programs.

Competitive Pressure In EGFR Exon20The EGFR exon20 lung cancer space is becoming crowded with multiple peer programs and some competitors materially ahead in first-line development, which could limit market share and pricing power for the company's drug.

Tolerability And Durability UncertaintyEnozertinib's relatively high rate of dose reductions combined with several unconfirmed responses creates uncertainty around tolerability and durability of benefit, which could complicate later-stage success.

Oric Pharmaceuticals News

Oric selloff brings favorable entry point, says H.C. Wainwright

H.C. Wainwright says the share pullback on Ipsen (IPSEY) voluntarily withdrawing Tazverik from the market creates a favorable...

10d ago

ORIC

Oric Pharmaceuticals reports Q4 revenue C$17.39M vs. C$18.04M last year

The company said, “2025 marked an important step in our transition toward a platform-driven business model. Subscription and...

11d ago

ORIC

Oric Pharmaceuticals selloff a buying opportunity, says JPMorgan

JPMorgan analyst Anupam Rama says Oric Pharmaceuticals (ORIC) shares were down 15% yesterday with Ipsen’s voluntary withdrawal of...

13d ago

ORIC

Cantor says Oric move down on tazemetostat withdrawal an ‘over-reaction’

Cantor Fitzgerald analyst Prakhar Agrawal notes Oric Pharmaceuticals (ORIC) shares are down 15% after Ipsen (IPSEY) announced that...

14d ago

ORIC

Midday Fly By: Hims & Hers reaches Novo deal, Live Nation settles with DOJ

The major averages were lower near noon, but well off earlier lows, amid the continued spike in oil...

14d ago

Oric Pharmaceuticals falls after peer Ipsen voluntarily withdraws Tazverik

Shares of Oric Pharmaceuticals (ORIC) are down $1.63, or 12%, to $12.09 in Monday morning trading after rival...

14d ago

ORIC

Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $25 from $23...

27d ago

ORIC

Oric Pharmaceuticals price target raised to $17 from $16 at Citi

Citi raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $17 from $16 and keeps a Buy...

27d ago

ORIC

Oric Pharmaceuticals reports Q4 EPS (30c), consensus (37c)

“2025 was a transformational year for ORIC highlighted by clinical data that further demonstrated the potential best-in-class profiles...

27d ago

ORIC

Oric Pharmaceuticals expects cash to fund operations into 2H 2028

Cash, cash equivalents and investments totaled $392.3 million as of December 31, 2025, which includes net proceeds of...

27d ago

ORIC

Constructive Buy Thesis on ORIC Driven by Differentiated PRC2 Biology and Manageable Safety Profile for Rinzimetostat

Analyst Yigal Nochomovitz of Citi maintained a Buy rating on Oric Pharmaceuticals, retaining the price target of $17.00....

13d ago

ORIC

ORIC Pharmaceuticals: Differentiated PRC2 Inhibitor Rinzimetostat Mitigates Sector Safety Overhang and Supports Buy Rating

Oric Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from...

14d ago

ORIC

Oric Pharmaceuticals Launches New 2026 ATM Share Program

Oric Pharmaceuticals ( ($ORIC) ) just unveiled an update. On May 6, 2021, ORIC Pharmaceuticals, Inc. entered into...

27d ago

ORIC

Piper Sandler Puts its Weight Behind 2 ‘Strong Buy’ Cancer Stocks

Cancer remains one of the world’s deadliest challenges. Second only to heart disease, it claims one in every...

2M ago

OLMA

ORIC

ORIC FAQ

What was Oric Pharmaceuticals’s price range in the past 12 months?

Oric Pharmaceuticals lowest stock price was $3.90 and its highest was $14.93 in the past 12 months.

What is Oric Pharmaceuticals’s market cap?

Oric Pharmaceuticals’s market cap is $1.12B.

When is Oric Pharmaceuticals’s upcoming earnings report date?

Oric Pharmaceuticals’s upcoming earnings report date is May 11, 2026 which is in 49 days.

How were Oric Pharmaceuticals’s earnings last quarter?

Oric Pharmaceuticals released its earnings results on Feb 23, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.34 by $0.04.

Is Oric Pharmaceuticals overvalued?

According to Wall Street analysts Oric Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oric Pharmaceuticals pay dividends?

Oric Pharmaceuticals does not currently pay dividends.

What is Oric Pharmaceuticals’s EPS estimate?

Oric Pharmaceuticals’s EPS estimate is -0.32.

How many shares outstanding does Oric Pharmaceuticals have?

Oric Pharmaceuticals has 100,358,240 shares outstanding.

What happened to Oric Pharmaceuticals’s price movement after its last earnings report?

Oric Pharmaceuticals reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.34. Following the earnings report the stock price went up 14.603%.

Which hedge fund is a major shareholder of Oric Pharmaceuticals?

Currently, no hedge funds are holding shares in ORIC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oric Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-38.79%

Trailing 12-Months

Asset Growth

48.52%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Oric Pharmaceuticals (ORIC) Earnings & Revenues

Historic Earnings Reports

ORIC Stock 12 Month Forecast

Average Price Target

$20.30

▲(81.90% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","15":"$15","26":"$26","9.5":"$9.5","20.5":"$20.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.5,15,20.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.88,14.735384615384616,15.590769230769231,16.446153846153848,17.301538461538463,18.15692307692308,19.012307692307694,19.86769230769231,20.723076923076924,21.57846153846154,22.433846153846154,23.28923076923077,24.144615384615385,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.88,14.373846153846154,14.867692307692309,15.361538461538462,15.855384615384615,16.349230769230772,16.843076923076925,17.336923076923078,17.83076923076923,18.324615384615385,18.81846153846154,19.31230769230769,19.806153846153848,{"y":20.3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.88,13.65846153846154,13.436923076923078,13.215384615384616,12.993846153846155,12.772307692307693,12.55076923076923,12.329230769230769,12.107692307692307,11.886153846153846,11.664615384615384,11.443076923076923,11.221538461538461,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.03,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.47,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.38,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.15,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.18,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.88,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >